# Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

> **NCT02465515** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 9463 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Albiglutide 30 mg
- **BIOLOGICAL:** Albiglutide 50 mg
- **BIOLOGICAL:** Albiglutide matching placebo

## Key facts

- **NCT ID:** NCT02465515
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-01
- **Primary completion:** 2018-02-20
- **Final completion:** 2018-03-14
- **Target enrollment:** 9463 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465515, "Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02465515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*